1lwai I, Hatao M, Naganuma M, et al. UVA - induced immune suppression through an oxidative pathway. J Invest Dermatol 1999;112:19-24.
2FJ- Mofty M, Mostafa W, E1 - Darouty M, et al. Different low doses of broad - band UVA in the treatment of morphea and systemic sclerosis. Photodermatol Photoimmunol Photomed 2004 ; 20 : 148 -156.
3Kreuter A, Breukmann F, Uhle A, et al. Low- dose UVAI phototherapy in systemic sclerosis: effects on acrosclerosis. J Am Acad Dermatol 2004;50:740 - 747.
4Dumay O, Karam A, Vian L, et al. Ultraviolet AI exposure of human skin results in langerhans cell depletion and reduction of epidermal antigen- presenting cell function: partial protection by a broad- spectrum sunscreen. Br J Dermatol 2001 ; 144:1161 - 1168.
5Tin L, Yamauchi R, Tsuji T, et al. The expression of matrix metalloproteiuase - 1 mRNA induced by ultraviolet Al (340 - 400 nm)is phototherapy relevant to the glutathione (GSH) content in skin fibroblasts of systemic sclerosis. J Dermatol 2003;30:173 - 180.
6von Kobyletzki G, Uhle A, Pieck C, et al. Acrosclerosis in patients with systemic sclerosis respond to low - close UV - Al phototherapy.Arch Dermatol 2000;136:275 - 276.
7Morita A, Kobayashi K, lsomura I, et al. Ultraviolet Al (340-400nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dennatol 2000;43 : 670 - 674.
8Hofer A, Soyer HP. Oral psoralen - UV - A for systemic scleroderma. Arch Dermatol 1999;135:603 - 604.
9Pasic A, Ceovic R, Lipozencic J, et al. phototherapy in pediatric patients. Pediatr Dermatol 2003 ; 20 : 71 - 77.
10Sato S, Kodera M, Hasegawa M, et al. Takehara K Antinucleosome antibodty is a major autoantibody in localized scleroderma. Br J Dermatol 2004 ; 151 : 1182 - 1188.
